Decode Pathways. Define Therapies. Match the Right Patient

---

We employ PathwayPersona (TM) platform to address high cost of failures in therapeutics and diagnostics development. This is accompanied through novel data driven approaches that elucidate disease, targets, drug interactions, and enhance drug efficacy. 

PathwayPersona (TM) uniquely positioned to unravel cancer heterogeneity in tumor microenvironment by mapping intracellular signaling pathways and generating novel hypotheses that extend beyond known cell signaling pathways. 

Cellazon can help you validate your targets and build clinically relevant insights. 

Cellazon was founded on April 7th, 2025 with the goal of offering its expertise in advanced AI/ ML, for multi-omics computational data analysis to help develop better Dx biomarkers and therapeutics through collaborations with precision medicine teams with access to patient-derived databases

Cellazon's expertise in computational analysis uncovers the signaling pathways that drive cell-to-cell communication in disease. By identifying novel therapeutic targets and biomarkers, we aim to transform the treatment landscape across a range of indications. Leveraging our proprietary in-vivo immune cell engineering platform, we aim to design and develop effective cell therapies for these targets

At Cellazon, we are committed to ethical conduct in all we do and united by a shared mission to redefine disease biology and unlock new and highly personalized therapeutic possibilities that are safe, effective, and accessible to all